Showing results (91-100 of 144) with videos related to

Sort By:
Pageof 15
Molecular Diagnosis & Therapy|September 6, 2015
Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR TherapyPatricia Llovet, Javier Sastre, Julián Sanz Ortega, et al.
BMC Cancer|April 18, 2015
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological featuresRamon Salazar, Jaume Capdevila, Berta Laquente, et al.
Molecular and Clinical Oncology|July 3, 2015
Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE studyJavier DE Castro Carpeño, Pere Gascón-Vilaplana, Ana Maria Casas-Fernández-DE Tejerina, et al.
The Oncologist|May 31, 2012
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors studyJavier Sastre, M Luisa Maestro, Auxiliadora Gómez-España, et al.
Critical Reviews in Oncology/Hematology|December 30, 2008
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III studyJavier Sastre, Enrique Aranda, Bartomeu Massutí, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinomaFernando Rivera, Maica Galán, Josep Tabernero, et al.
Frontiers in Psychology|June 6, 2022
Efficacy of a Combined Acceptance and Commitment Intervention to Improve Psychological Flexibility and Associated Symptoms in Cancer Patients: Study Protocol for a Randomized Controlled TrialFrancisco García-Torres, Ángel Gómez-Solís, Sebastián Rubio García, et al.
British Journal of Cancer|August 1, 2019
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patientsElena Elez, Carles Pericay, Manuel Valladares-Ayerbes, et al.
Cancer Chemotherapy and Pharmacology|March 4, 2010
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinomaFernando Rivera, Maica Galán, Josep Tabernero, et al.
BMC Cancer|November 28, 2020
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term resultsRamón Salazar, Jaume Capdevila, Jose Luis Manzano, et al.
Pageof 15